Esperion Corp - ESPR Forward Price-to-Revenue Multiple

Corporate emblem and logo of Esperion (ESPR)

Esperion Therapeutics (ESPR) revenue is based on the stable production of lipid-lowering agents via contract manufacturing capacities. The forward P/S trajectory visualizes the dynamics of this valuation, where the metric stands at 2.00. Constant demand for chronic disease therapy ensures predictable sales, while exclusive patents and strict FDA oversight create significant barriers to entry for new players in cardiology.

ESPR (esperion.com) Price to Expected Revenue Ratio history from 07/04/2022 to 07/25/2026

ESPR (Esperion Corp): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Esperion|ESPR - Broker Consensus Forecast
- issuer market value details:
Market Valuation Esperion Corp|ESPR - Value Adjusted for Debt and Cash
- business book valuation details:
Accounting Value per Share Esperion Therapeutics|ESPR - Total Net Assets|Market Capitalization to Book Value Ratio esperion.com|ESPR - Aggregate Asset Value
- debt and solvency information:
Total Debt to Capital Esperion Therapeutics|ESPR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Esperion Therapeutics|ESPR - Aggregate Debt Obligations|Debts to Book Capitalization Esperion Corp|ESPR - Company Long-Term Debts|Company Short-Term Debt Esperion Therapeutics|Quick Ratio esperion.com
- net income and valuation multiples indicators:
ESPR - Company Net Income|Future Profit Esperion Therapeutics|ESPR - P/E Multiple|Projected Price to Earnings Esperion Therapeutics Inc|ESPR - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Esperion Corp|ESPR - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Esperion Therapeutics|ESPR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months esperion.com|ESPR - Expected net earnings per share growth this year|Earnings growth forecast for next year Esperion Therapeutics
- issuer revenue and sales details:
ESPR - Company Total Revenue|Company Projected Revenue Esperion|ESPR - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Esperion Corp
Summary company analysis:Esperion ESPR
Product sample of Esperion Therapeutics

Forward P/S is calculated as the ratio of current market capitalization to expected annual revenue. This indicator allows for an assessment of the business valuation's fairness relative to its projected cash flows, eliminating the risk of investing in a stagnating asset. The competence of Esperion Therapeutics (ESPR) management in scaling sales of cardiovascular drugs directly impacts the accuracy of these expectations. An analysis of the forward P/S trend confirms that market quotes are aligned with the company's potential for commercial growth.

Competitors of Esperion Therapeutics

Price-to-Projected Revenue Ratio Regeneron REGN|IRTC: Market Cap to Projected Revenue|LNTH: Forward Price-to-Revenue Multiple|Forward Price to Sales MLYS (Mineralys Corp)|HTFL (heartflow.com) - Forward Price-to-Revenue Multiple|KMTS: Price to Expected Revenue Ratio|AMRN (Amarin) - Forward P/S Multiple|AVR: Forward Price to Sales|Forward P/S Multiple TNYA|CVRX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Milestone Pharmaceuticals MIST|Forward Price to Sales CRDL|HeartBeam - Forward P/S Multiple|TENX - Forward P/S Multiple|Adagio Medical Holdings Inc. (ADGM) - Price-to-Projected Revenue Ratio|Future Price to Revenue BCDA (BioCardia Inc)|VTAK (Catheter Precision) - Forward P/S Multiple|Market Cap to Future Revenue Ratio ARCA Bio ABIO|Forward Price-to-Revenue Multiple ACST (Acasti Pharma)|Forward P/S Multiple Aerovate Therapeutics Inc. (AVTE)|Verve Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio WINT (Windtree Therapeutics Inc.)